相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease
Yingfei Xi et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review
Rohit Loomba et al.
GASTROENTEROLOGY (2020)
Modulation of SIRT1-mediated signaling cascades in the liver contributes to the amelioration of nonalcoholic steatohepatitis in high fat fed middle-aged LDL receptor knockout mice by dihydromyricetin
Yi Zeng et al.
BIOCHEMICAL PHARMACOLOGY (2020)
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents
Agrin Moeini et al.
GASTROENTEROLOGY (2019)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration
Bin Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Farnesoid X Receptor Ablation Sensitizes Mice to Hepatitis B Virus X Protein-Induced Hepatocarcinogenesis
Yongdong Niu et al.
HEPATOLOGY (2017)
Hepatic FXR/SHP Axis Modulates Systemic Glucose and Fatty Acid Homeostasis in Aged Mice
Kang Ho Kim et al.
HEPATOLOGY (2017)
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway
Xiongyan Wu et al.
ONCOTARGET (2017)
The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
Yasmeen M. Attia et al.
SCIENTIFIC REPORTS (2017)
Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation
Xi Xiong et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine
Norihiro Kishida et al.
BMC GASTROENTEROLOGY (2016)
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
Claudia D. Fuchs et al.
SEMINARS IN LIVER DISEASE (2016)
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
Natalia Gomez-Ospina et al.
NATURE COMMUNICATIONS (2016)
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
Len Verbeke et al.
SCIENTIFIC REPORTS (2016)
Animal Models Correlating Immune Cells for the Development of NAFLD/NASH
Srikanth Iyer et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2015)
FXR silencing in human colon cancer by DNA methylation and KRAS signaling
Ann M. Bailey et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2014)
Hepatitis B virus-induced hepatocellular carcinoma
Cheng Xu et al.
CANCER LETTERS (2014)
SIRT1 Controls Liver Regeneration by Regulating Bile Acid Metabolism Through Farnesoid X Receptor and Mammalian Target of Rapamycin Signaling
Juan L. Garcia-Rodriguez et al.
HEPATOLOGY (2014)
Nonalcoholic Steatohepatitis Is the Most Rapidly Growing Indication for Liver Transplantation in Patients With Hepatocellular Carcinoma in the U. S.
Robert J. Wong et al.
HEPATOLOGY (2014)
Potency of Individual Bile Acids to Regulate Bile Acid Synthesis and Transport Genes in Primary Human Hepatocyte Cultures
Jie Liu et al.
TOXICOLOGICAL SCIENCES (2014)
Mechanisms of STAT3 activation in the liver of FXR knockout mice
Guodong Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
Cellular and molecular mechanisms of hepatocellular carcinoma: an update
Rajagopal N. Aravalli et al.
ARCHIVES OF TOXICOLOGY (2013)
Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer
Yanjun Jiang et al.
HEPATOLOGY (2013)
Resveratrol suppresses the STAT3 signaling pathway and inhibits proliferation of high glucose-exposed HepG2 cells partly through SIRT1
Yongguang Li et al.
ONCOLOGY REPORTS (2013)
Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma
Hongying Su et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Downregulation of Human Farnesoid X Receptor by miR-421 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells
Yan Zhang et al.
MOLECULAR CANCER RESEARCH (2012)
SIRT1 and c-Myc Promote Liver Tumor Cell Survival and Predict Poor Survival of Human Hepatocellular Carcinomas
Kyu Yun Jang et al.
PLOS ONE (2012)
Sirtuin 1 in lipid metabolism and obesity
Thaddeus T. Schug et al.
ANNALS OF MEDICINE (2011)
Role of nuclear receptor SHP in metabolism and cancer
Yuxia Zhang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis
Sayeepriyadarshini Anakk et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Farnesoid X Receptor Activation Improves Erectile Function in Animal Models of Metabolic Syndrome and Diabetes
Linda Vignozzi et al.
JOURNAL OF SEXUAL MEDICINE (2011)
Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
Rian M. Nijmeijer et al.
PLOS ONE (2011)
Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells
Reeti Behera et al.
CARCINOGENESIS (2010)
A Pathway Involving Farnesoid X Receptor and Small Heterodimer Partner Positively Regulates Hepatic Sirtuin 1 Levels via MicroRNA-34a Inhibition
Jiyoung Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Farnesoid X Receptor Activation Mediates Head-to-Tail Chromatin Looping in the Nr0b2 Gene Encoding Small Heterodimer Partner
Guodong Li et al.
MOLECULAR ENDOCRINOLOGY (2010)
Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand
Jiang Li et al.
PLOS ONE (2010)
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
Daniel Herranz et al.
NATURE COMMUNICATIONS (2010)
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Marcin Kortylewski et al.
CANCER CELL (2009)
MiR-34, SIRT1 and p53 The feedback loop
Munekazu Yamakuchi et al.
CELL CYCLE (2009)
FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States
Jongsook Kim Kemper et al.
CELL METABOLISM (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications
Evi N. Debruyne et al.
CLINICA CHIMICA ACTA (2008)
IL-24 Induces Apoptosis of Chronic Lymphocytic Leukemia B Cells Engaged into the Cell Cycle through Dephosphorylation of STAT3 and Stabilization of p53 Expression
Alexander Sainz-Perez et al.
JOURNAL OF IMMUNOLOGY (2008)
Analyzing real-time PCR data by the comparative C-T method
Thomas D. Schmittgen et al.
NATURE PROTOCOLS (2008)
Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor
Fan Yang et al.
CANCER RESEARCH (2007)
Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration
WD Huang et al.
SCIENCE (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
The Farnesoid X receptor - A molecular link between bile acid and lipid and glucose metabolism
T Claudel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms
S Haga et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
SOCS3 negatively regulates IL-6 signaling in vivo
BA Croker et al.
NATURE IMMUNOLOGY (2003)
The bile acid glycochenodeoxycholate induces TRAIL-receptor 2/DR5 expression and apoptosis
H Higuchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
